Since Navitoclax selectively targets activated PSCs, inducing their death and downregulating markers of activation, we proceeded to evaluate the impact of BCL2 inhibition in vivo, using a cerulein-induced model of chronic pancreatitis (CP), to assess whether this strategy could mitigate pancreatic fibrosis. Here, BCL2 is linked to chronic pancreatitis.